AI Article Synopsis
Article Abstract
Background: The purpose of this study was to compare the success rates of 70 patients from the same database, each with an ectopic pregnancy (EP) that was treated with either the single- or multi-dose methotrexate (MTX) protocols for unruptured EPs.
Materials And Methods: This study was a blinded, randomized clinical trial. Treatment protocols were either single- (50 mg/m(2)) dose MTX or multi-dose (1 mg/kg MTX + 0.1 mg/kg folinic acid). There were 35 cases in each group. The outcome was measured by adverse events, resolution of pregnancy without surgical treatment, success rate of MTX treatment, and fertility outcome in each group.
Results: With the single-dose protocol, response to treatment was considered successful in 29 (82.9%) patients; in the multi-dose protocol 31 (88.6%) responded to treatment. The difference between success rates in the groups was not statistically significant (p=0.587). In the singledose group, 2 (5.7%) patients and in the multi-dose group, 6 (17.2%) patients had complications (p=0.28). Of the 14 patients in the single-dose group. Clinical pregnancy occurred in 9 (75%) whereas clinical pregnancy occurred in 3 (25%) patients from the multi-dose group. Infertility was seen in 4 (33.3%) patients in the single-dose group and in 8 (66.7%) in the multi-dose group.
Conclusion: We believe that the single-dose MTX protocol could be as successful as multi-dose MTX for the treatment of EP. It is effective, cost-effective, and associated with better fertility outcomes than the multi-dose MTX protocol (Registration Number: IRCT201112178435N1).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850298 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of RANKL inhibition.
J Bone Miner Res
January 2025
Cancer Ecosystems Program, Garvan Institute of Medical Research, Sydney, NSW, Australia.
Rebound bone loss following denosumab discontinuation is an important barrier in the effective long-term treatment of skeletal disorders. This is driven by increased osteoclastic bone resorption following the offset of RANKL inhibition, and sequential osteoclast-directed therapy has been utilised to mitigate this. However, current sequential treatment strategies intervene following the offset of RANKL inhibition and this approach fails to consistently prevent bone loss.
View Article and Find Full Text PDFMulti-dose formulation and clinical deployment of [Y]Y-labeled hydroxyapatite (HA) microparticles for radiation synovectomy in India- the inherent intricacies.
Appl Radiat Isot
March 2025
Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, 400085, India; Homi Bhabha National Institute, Mumbai, 400094, India. Electronic address:
The present article describes intricate details involved in the formulation and quality control of 113 ready to use doses of [Y]Y-labeled hydroxyapatite (HA) microparticles for clinical use in radiation synovectomy using Y produced by (n,γ) route. Yttrium-90 was produced with a specific activity of 720 ± 95 MBq/mg of Y and radionuclidic purity of >99.9%.
View Article and Find Full Text PDFFactors Influencing Medication Adherence in Heart Failure Patients-A Survey among Cardiac Healthcare Providers.
Clin Pharmacol Ther
December 2024
Department of Cardiology, Landspitali - The National University Hospital of Iceland, Reykjavík, Iceland.
Adhering to medication regimens is key behavior to alleviate symptoms and slow disease progression in heart failure (HF). This study explores cardiac healthcare providers' perceptions and experiences of factors influencing medication adherence (MA) in HF patients, with findings contributing to developing a HF-specific MA assessment scale. Using a cross-sectional, mixed methods design, we conducted an online survey with both closed and open-ended questions distributed to cardiac healthcare providers, working at the National University Hospital in Iceland.
View Article and Find Full Text PDFSafety, Pharmacokinetics and Antiviral Efficacy of Capsid Assembly Modulator Freethiadine in Healthy Volunteers and Chronic Hepatitis B Patients.
Liver Int
January 2025
Phase I Clinical Trial Center, the First Hospital of Jilin University, Jilin, China.
Background And Aims: Freethiadine is a novel hepatitis B virus capsid assembly modulator. Herein, we report the safety, tolerability, pharmacokinetics and 28-day antiviral activities of freethiadine.
Methods: The study consisted of two parts.
The effects of chronic neuropathic pain on the self-administration of highly potent MOR agonist, fentanyl.
bioRxiv
November 2024
Department of Pharmacology, University of Michigan, Ann Arbor Michigan, 48109.
There is significant overlap between chronic pain and opioid use disorder (OUD) patient populations such that approximately 50-65% of chronic pain patients have OUD. However, we understand relatively little about how chronic, long-lasting pain states alter ongoing self-administration of opioid analgesics. Thus, the goal of this study was to determine if chronic neuropathic pain altered the ongoing self-administration of fentanyl, or a non-opioid drug of abuse, cocaine.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!